Description

IDEX: The Life Sciences Headwind And China Pressure Are What The Hold Reflects!

IDEX Corporation reported a strong start to fiscal year 2026 with first quarter results exceeding expectations across several key financial metrics. The company posted organic sales growth of 5%, driven primarily by the Health & Science Technologies (HST) segment, which grew 11% organically. Orders increased 10% organically, led by a 17% rise in HST orders and 9% growth in Fluid & Metering Technologies (FMT) orders, while Fire & Safety/Diversified Products (FSDP) orders declined 4% organically. Adjusted EBITDA margin expanded by 50 basis points year-over-year to 26%, reflecting productivity gains, volume leverage, and pricing improvements. Within HST, growth was fueled by secular drivers in high-value markets such as data centers, semiconductors, space, and defense, supported by a strong backlog that improves visibility into future performance. Pharma continued to perform well, although some pressures in life sciences related to funding and China market conditions persisted.